Thus, the use of targeted therapies such as daratumumab is justified due to the inhibition of tumor growth by binding to the CD38 glycoprotein with high affinity, with the activation of immune-mediated molecular mechanisms [47]. This evidence concerns the gene CD38 and neoplasm.